Economy/Home · Economy

Hanmi Science Shares Fall to 43,050 Won... Q3 Operating Profit Down 51%, Hopes for Turnaround on Q4 Tech Export Upfront Payments

Hanmi Science declined in intraday trading on the 3rd, trading in the 43,000-won range. While revenue for the third quarter of this year increased, operating profit fell by more than half compared to the same period last year. The securities industry views the base effect from last year's technology

Wooil Shim
Staff Reporter
7 min read
Hanmi Science Shares Fall to 43,050 Won... Q3 Operating Profit Down 51%, Hopes for Turnaround on Q4 Tech Export Upfront Payments
CBC News

Hanmi Science declined in intraday trading on the 3rd, trading in the 43,000-won range. While revenue for the third quarter of this year increased, operating profit fell by more than half compared to the same period last year. The securities industry views the base effect from last year's technology export revenue as the cause of the weak performance, but is watching the possibility that performance will improve in the fourth quarter as upfront payments from technology export contracts flow in.

In the morning stock market session on the 3rd, Hanmi Science was trading at 43,050 won, down 450 won from the previous trading day. This represents a 1.03% decline from the previous day's closing price of 43,500 won.

According to an analysis by Sangsangin Securities, Hanmi Science's third-quarter 2026 consolidated revenue came to 362.9 billion won, up 5.9% from the same period last year. In contrast, operating profit was 19.2 billion won, down 51.3% year-on-year.

Behind the sharp drop in profitability despite revenue growth lies the technology export revenue from Hanmi Pharmaceutical that was reflected in last year's third-quarter results. Sangsangin Securities explained that the technology export-related revenue generated last year raised the comparison baseline, and this base effect contributed to the decline in operating profit.

The holding company business segment of Hanmi Science derives its main revenue from technology export royalties from Hanmi Pharmaceutical and profits related to subsidiaries, making it a structure in which earnings volatility increases depending on when technology export revenue is reflected. In fact, the holding segment's revenue in the third quarter of this year declined from the same period last year, and Sangsangin Securities cited the fact that the upfront payment from the technology export related to HM17321 was not reflected in this quarter's results as a factor in the decline.

However, the possibility has been raised that the trend could change in the fourth quarter. This is because if the upfront payments under technology export contracts are reflected in earnings as scheduled, they could contribute to improving the holding segment's profitability. In particular, an additional technology export contract signed on October 30th is also drawing attention. Sangsangin Securities analyzed that the upfront payment arising from that contract may be reflected in future earnings.

With technology export contracts, quarterly results can vary depending on when revenue is recognized, such as contract payments and technology fees for each development stage. Therefore, when evaluating Hanmi Science's future performance, it is necessary to examine not only new contract signings but also the timing of when contract-based revenue is actually reflected in the accounts. Sangsangin Securities positively assessed Hanmi Science's mid- to long-term growth potential based on the possibility of continued inflows of technology export fee revenue.

Amid the weak third-quarter operating profit, whether the fourth-quarter technology export upfront payments will be reflected in earnings has emerged as a key point to watch. With Hanmi Science's share price moving in the 43,000-won range, revenue recognition from technology export contracts and changes in the holding segment's performance are expected to draw attention.

[This article was written based on intraday stock prices and securities firm analyses, and does not recommend buying or selling any particular stock. Stock investments may result in loss of principal, and investment decisions and responsibilities rest with the investor. AI provided partial assistance.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.